Venofer

Iron sucrose.

Each 5 ml ampoule of Venofer contains 100 mg iron as iron sucrose [iron(III)-hydroxide sucrose complex] corresponding to 20 mg iron per ml.
Excipients/Inactive Ingredients: Water for injection, Sodium hydroxide (for pH adjustment).

Pharmacotherapeutic group: Anti-anaemic preparation, iron, parenteral preparation. ATC code: B03 AC.
Pharmacology: Pharmacodynamics: Mechanism of action: Iron sucrose, the active ingredient of Venofer, is composed of a polynuclear iron(III)-hydroxide core surrounded by a large number of non-covalently bound sucrose molecules. The complex has a weight average molecular weight (Mw) of approximately 43 kDa. The polynuclear iron core has a structure similar to that of the core of the physiological iron storage protein ferritin. The complex is designed to provide, in a controlled manner, utilisable iron for the iron transport and storage proteins in the body (i.e., transferrin and ferritin, respectively).
Following intravenous administration, the polynuclear iron core from the complex is taken up predominantly by the reticuloendothelial system in the liver, spleen, and bone marrow. In a second step, the iron is used for the synthesis of Hb, myoglobin and other iron-containing enzymes, or stored primarily in the liver in the form of ferritin.
Clinical efficacy and safety: Nephrology: Dialysis dependent chronic kidney disease: Study LU98001 was a prospective, open-label, single arm study to investigate the efficacy and safety of Venofer in hemodialysis patients with iron deficiency anaemia (Hb concentration >8 and <11.0 g/dl, TSAT <20%, and serum ferritin <300 μg/l) who were receiving rHuEPO therapy. A total of 77 patients [44 (57%) male; mean age 62.5 (range: 24-85 years)] participated in the study and received 100 mg of iron as Venofer administered via the dialysis line for up to 10 sessions over 3 to 4 weeks. A mean total dose of 983.1 ±105.63 mg of iron as Venofer was administered over a mean of 9.8 ±1.06 dialysis sessions. A Hb >11 g/dl was attained in 39/45 (87%; 95% CI 76.5, 96.9) of evaluable patients. Similar results were observed in the ITT population 60/77 (78%; 95% CI 68.5, 87.3). The maximum increase in serum ferritin from 83.6 ±11.69 μg/l to 360.3 ±36.81 μg/l (n=41) was seen at the completion of treatment with Venofer. The maximum increase in TSAT from 17.1 ±1.5% to 27.6 ±2.7% (n=41) was seen at the 5-week follow-up visit.
Non-dialysis dependent chronic kidney disease: Study 1VEN03027 was an open-label, randomised study comparing Venofer and oral ferrous sulfate in adult patients with renal insufficiency and iron deficiency anemia (Hb ≤11.0 g/dl, serum ferritin ≤300 μg/l, and TSAT ≤25%) with or without rHuEPO therapy. Patients were randomized to 1000 mg of iron as Venofer (500 mg infusion over 3.5 to 4 hours on Days 0 and 14, or 200 mg injections administered over 2 to 5 minutes on 5 different occasions from Day 0 to Day 14) or oral ferrous sulfate 325 mg (65 mg iron), 3 times daily for 56 days. A total of 91 patients were included in each treatment group. A statistically significant greater proportion of patients in the Venofer group (35/79; 44.3%) compared to the oral iron group (23/82; 28.0%) had an increase in Hb >1.0 g/dl during the study (p=0.0344). A clinical response (defined as Hb increase ≥1.0 g/dl and serum ferritin increase ≥160 μg/l) was more frequently observed in patients treated with Venofer (31/79; 39.2%) compared to oral iron (1/82; 1.2%); p<0.0001.
Gastroenterology: A randomised, controlled study compared Venofer with oral iron in 91 patients with irritable bowel disease and anaemia (Hb <11.5 g/dl). Patients were randomised to receive either oral ferrous sulfate tablets 200 mg twice daily (n=46) or Venofer (n=45) given as either a single I.V. dose of 200 mg of iron once per week or every second week for 20 weeks. Forty-three patients in the Venofer group completed the study compared to 35 patients in the oral iron group (p=0.0009). At the end of treatment, 66% of patients in the Venofer group had an increase in Hb ≥2.0 g/dl compared to 47% in the oral iron group (p=0.07). In the oral iron group, 41% of patients had anaemia at the end of study compared to 16% in the Venofer group (p=0.007). Forty-two percent of patients in the Venofer group reached their reference Hb (15 g/dl in males and 13 g/dl in females) compared to 22% in the oral iron group (p=0.04).
Post partum: A prospective, randomised, controlled trial in 43 women with postpartum iron deficiency anaemia (Hb <9 g/dl and serum ferritin <15 μg/l at 24-48 hours post-delivery) compared 2 x 200 mg of iron as Venofer given on Days 2 and 4 (n=22) to 200 mg of oral iron as ferrous sulfate given twice daily for 6 weeks (n=21). Significantly higher Hb levels were observed in the Venofer group compared to the oral iron group on Days 5 and 14 (p <0.01). The mean increase in Hb from baseline at Day 5 was 2.5 g/dl in the Venofer group and 0.7 g/dl in the oral iron group. By Day 40 there was no significant difference in Hb levels between the treatment groups. There was a significant increase in serum ferritin in the Venofer group by Day 5 and the serum ferritin remained significantly higher in the Venofer group compared to the oral iron group throughout the study (p<0.01 at Days 5 and 14 and p<0.05 at Day 40).
Pregnancy: In a randomised, open label study 90 women in their third trimester of pregnancy with iron deficiency anaemia (Hb 8 to 10.5 g/dl and serum ferritin <13 μg/l) were randomized to Venofer (n=45) or oral iron polymaltose complex (n=45). The individually calculated total dose of iron as Venofer was administered over 5 days with a maximum single dose of 200 mg given as an infusion and a maximum daily dose of 400 mg iron. The oral iron group received 100 mg iron as tablets thrice daily until delivery. The change in Hb from baseline was significantly greater in the Venofer group compared to the oral iron group at day 28 and at delivery (p<0.01). At delivery the number of patients reaching Hb target was 43 (95.6%) and 28 (62.2%) in the Venofer and oral iron groups, respectively (p<0.001). Serum ferritin values increased significantly over time in both the Venofer (p<0.05) and oral iron (p<0.05) groups.
Pharmacokinetics: Distribution: The ferrokinetics of iron sucrose labelled with 52Fe and 59Fe were assessed in 6 patients with anaemia and chronic renal failure. In the first 6-8 hours, 52Fe was taken up by the liver, spleen and bone marrow. The radioactive uptake by the macrophage-rich spleen is considered to be representative of the reticuloendothelial iron uptake.
Following intravenous injection of a single 100 mg iron dose of iron sucrose in healthy volunteers, maximum total serum iron concentrations were attained 10 minutes after injection and had an average concentration of 538 μmol/l. The volume of distribution of the central compartment corresponded well to the volume of plasma (approximately 3 litres).
Biotransformation: Upon injection, sucrose largely dissociates and the polynuclear iron core is mainly taken up by the reticuloendothelial system of the liver, spleen, and bone marrow. At 4 weeks after administration, red cell iron utilization ranged from 59 to 97%.
Elimination: The iron sucrose complex has a weight average molecular weight (Mw) of approximately 43 kDa, which is sufficiently large to prevent renal elimination. Renal elimination of iron, occurring in the first 4 hours after injection of a Venofer dose of 100 mg iron, corresponded to less than 5% of the dose. After 24 hours, the total serum iron concentration was reduced to the pre-dose level. Renal elimination of sucrose was about 75% of the administered dose.
Toxicology: Preclinical safety data: Nonclinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity, genotoxicity and toxicity to reproduction and development.

Venofer is indicated for the treatment of iron deficiency in the following indications: Where there is a clinical need for a rapid iron supply; In patients who cannot tolerate oral iron therapy or who are non-compliant; Where oral iron preparations are ineffective (e.g., in active inflammatory bowel disease).
Venofer should only be administered where the indication is confirmed by appropriate investigations.

Posology: The cumulative dose of Venofer must be calculated for each patient individually and must not be exceeded.
Calculation of dosage: The total cumulative dose of Venofer, equivalent to the total iron deficit (mg), is determined by the haemoglobin level (Hb) and body weight (BW). The dose of Venofer must be individually calculated for each patient according to the total iron deficit calculated with the following Ganzoni formula, for example: (See equation.)

Click on icon to see table/diagram/image

Total amount of Venofer to be administered according to body weight, actual Hb level and target Hb level*: (See Table 1.)

Click on icon to see table/diagram/image

To convert Hb (mM) to Hb (g/dl), multiply the former by 1.6. If the total necessary dose exceeds the maximum allowed single dose, then the administration must be divided.
Calculation of dosage for iron replacement secondary to blood loss and to support autologous blood donation: The required Venofer dose to compensate for the iron deficit may be calculated according the following formulas: If the quantity of blood lost is known: The administration of 200 mg iron (10 ml of Venofer) should result in an increase in Hb approximately equivalent to 1 unit blood (400 ml with Hb=15 g/dl).
Iron to be replaced [mg] = Number of blood units lost x 200 mg or;
Amount of Venofer needed [ml] = Number of blood units lost x 10 ml.
If the Hb level is less than desired: Formula assumes that the storage iron does not need to be restored.
Iron to be replaced [mg] = BW [kg] x 2.4 (target Hb - actual Hb) [g/dl].
Example: For BW = 60 kg and Hb decrease = 1 g/dl.
⇒≅150 mg iron to be replaced; ⇒7.5 ml Venofer needed.
For the maximum tolerated single and weekly dose, see "Normal posology" and "Maximum tolerated single and weekly doses" as follows.
Normal posology: Adults: 5-10 ml of Venofer (100-200 mg iron) 1 to 3 times a week. For administration time and dilution ratio see "Method of administration" as follows.
Paediatric population: There is a moderate amount of data in children under study conditions. If there is a clinical need, it is recommended not to exceed 0.15 ml of Venofer (3 mg iron) per kg body weight not more than three times per week.
For administration time and dilution ratio see "Method of administration" as follows.
Maximum tolerated single and weekly doses: Adults: As an injection, maximum tolerated dose per day given not more than 3 times per week: 10 ml of Venofer (200 mg iron) injected over at least 10 minutes.
As an infusion, maximum tolerated dose per day given not more than once per week: Patients above 70 kg body weight: 500 mg iron (25 ml of Venofer) over at least 3½ hours;
Patients of 70 kg body weight and below: 7 mg iron/kg body weight over at least 3½ hours.
The infusion times given in "Method of administration" as follows should be strictly adhered to, even if the patient does not receive the maximum tolerated single dose.
Method of administration: Venofer must only be administered by the intravenous route. This may be by drip infusion, slow injection or directly into the venous line of the dialysis machine.
Intravenous drip infusion: Venofer must only be diluted in sterile 0.9% m/V sodium chloride (NaCl) solution. Dilution must take place immediately prior to infusion and the solution should be administered as follows: (See Table 2.)

Click on icon to see table/diagram/image

Intravenous injection: Venofer may be administered by slow intravenous injection at a rate of 1 ml undiluted solution per minute and not exceeding 10 ml (200 mg iron) per injection.
Injection into venous line of dialysis machine: Venofer may be administered during a haemodialysis session directly into the venous line of the dialysis machine under the same conditions as for intravenous injection.

Overdose can cause iron overload which may manifest itself as haemosiderosis. Overdose should be treated, as deemed necessary by the treating physician, with an iron chelating agent or according to standard medical practice.

The use of Venofer is contraindicated in the following conditions: Hypersensitivity to iron sucrose, Venofer or to any of its excipients listed in Description;
Anaemia not caused by iron deficiency;
Evidence of iron overload or hereditary utilisation of iron.

Parenterally administered iron preparations can cause allergic or anaphylactoid reactions, which can be potentially fatal. Therefore, anti-allergic treatment should be available along with cardio-pulmonary resuscitation facilities and procedures. Hypersensitivity reactions have also been reported after previously uneventful doses of parenteral iron complexes including iron sucrose. Each patient should be observed for adverse effects for at least 30 minutes following each Venofer injection. There have been reports of hypersensitivity reactions which progressed to Kounis syndrome (acute allergic coronary arteriospasm that can result in myocardial infarction, see Adverse Reactions).
In patients with a history of asthma, eczema, other atopic allergies or allergic reactions to other parenteral iron preparations, Venofer should be administered with caution as these patients may be particularly at risk of an allergic reaction. However, in several studies performed in patients who had a history of a hypersensitivity reaction to iron dextran or ferric gluconate, Venofer was shown to be well tolerated.
In patients with liver dysfunction, parenteral iron should only be administered after careful risk/benefit assessment. Parenteral iron administration should be avoided in patients with hepatic dysfunction where iron overload is a precipitating factor. Careful monitoring of iron status is recommended to avoid iron overload.
Parenteral iron should be used with caution in the case of acute or chronic infection. It is recommended that the administration of Venofer is stopped in patients with bacteremia. In patients with chronic infection, a risk/benefit evaluation should be performed.
Paravenous leakage must be avoided because leakage of Venofer at the injection site can lead to pain, inflammation and brown discolouration of the skin.
Effects on ability to drive and use machines: Venofer is unlikely to influence the ability to drive or use machines. However, if symptoms such as dizziness, confusion or light-headedness occur following the administration of Venofer, affected patients should not drive a car or use machines until the symptoms have abated.

Pregnancy: There is no or only a limited amount of data (less than 300 pregnancy outcomes) from the use of iron sucrose in pregnant women in the first trimester. A moderate amount of data (between 300-1,000 pregnancy outcomes) from the use of Venofer in pregnant women in the second and third trimester showed no safety concerns for the mother or newborn.
Venofer should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus, particularly during the first trimester (see Precautions).
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Breastfeeding: There is limited information on the excretion of iron in human milk following administration of intravenous iron sucrose. In one clinical study, 10 healthy breast-feeding mothers with iron deficiency received 100 mg iron in the form of iron sucrose. Four days after treatment, the iron content of the breast milk had not increased and there was no difference from the control group (n=5). It cannot be excluded that newborns/infants may be exposed to iron derived from Venofer via the mother's milk, therefore the risk/benefit should be assessed.
Preclinical data do not indicate direct or indirect harmful effects to the nursing child. In lactating rats treated with ⁵⁹Fe-labelled iron sucrose, low secretion of iron into the milk and transfer of iron into the offspring was observed. Non metabolised iron sucrose is unlikely to pass into the mother's milk.
Fertility: No effects of iron sucrose treatment were observed on fertility, mating performance and early embryonic development in rats.

The most commonly reported adverse drug reaction in clinical trials with Venofer was dysgeusia, which occurred with a rate of 4.5 events per 100 subjects. The most important serious adverse drug reactions associated with Venofer are hypersensitivity reactions, which occurred with a rate of 0.25 events per 100 subjects in clinical trials. Anaphylactoid/anaphylactic reactions were reported only in the post-marketing setting (estimated rate of less than 0.075 events per 100 subjects); fatalities have been reported. See Precautions.
The adverse drug reactions reported after the administration of Venofer in 4,046 subjects in clinical trials as well as those reported from the post-marketing setting are presented in the table as follows. (See Table 3.)

Click on icon to see table/diagram/image

As with all parenteral iron preparations, it is recommended that Venofer is not administered concomitantly with oral iron preparations since the absorption of oral iron may be reduced.

Incompatibilities: This medicinal product must not be mixed with other medicinal products except those mentioned in Special precautions for disposal and other handling as follows. There is the potential for precipitation and/or interaction if mixed with other solutions or medicinal products. The compatibility with containers other than glass, polyethylene and PVC is not known.
Special precautions for disposal and other handling: Ampoules should be visually inspected for sediment and damage before use. Use only those containing a sediment-free and homogenous solution.
Venofer must not be mixed with other medicinal products except sterile 0.9% m/V sodium chloride solution for dilution. For instructions on dilution of the product before administration, see Dosage & Administration.
The diluted solution must appear as brown and clear. Each ampoule of Venofer is intended for single use only.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Do not store above 30°C. Do not freeze. Store in the original package.
For storage conditions after dilution or first opening of the medicinal product, see Shelf life as follows.
Shelf life: Shelf-life of the product as packaged for sale: 2 years.
Shelf-life after first opening of the container: From a microbiological point of view, the product should be used immediately.
Shelf-life after dilution with sterile 0.9% m/V sodium chloride solution: Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C. However, from a microbiological point of view, the product should be used immediately after dilution. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C.

Vitamins & Minerals (Pre & Post Natal) / Antianemics

B03AC - Iron, parenteral preparations ; Used in the treatment of anemia

NP